Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Builders FirstSource, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Builders FirstSource, Inc. (BLDR $109.68), the largest distributor of building products for the residential new construction market in North America.

    Read more

  • AI and the Future of Healthcare Billing: A Breakthrough for Providers and Investors

    By automating routine tasks, AI streamlines operations, reduces manual labor, accelerates payment cycles, and more.

    Read more

  • Is AI Driving the Productivity Boom?

    While AI’s most significant impact may be yet to come, today’s productivity surge is driven less by artificial intelligence and more by post-pandemic investment cycles and tightening labor markets.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures